A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
- Conditions
- Influenza, Human
- Interventions
- Registration Number
- NCT05540522
- Lead Sponsor
- Pfizer
- Brief Summary
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
- Detailed Description
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a quadrivalent influenza modRNA vaccine (qIRV) encoding HA of 4 seasonally recommended strains (2 A strains and 2 B strains) compared to licensed quadrivalent influenza vaccine (QIV) in healthy adults 18 years of age and older.
Participants may be enrolled in either the reactogenicity subset, immunogenicity subset, or both/neither subset(s). Efficacy will be assessed in this study through surveillance for influenza-like illness.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45789
- Male or female participants ≥18 years of age at Visit 1 (Day 1).
- Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures.
- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
- Medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- Allergy to egg proteins (egg or egg products) or chicken proteins.
- Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), eg, for cancer or an autoimmune disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
- Receipt of blood/plasma products or immunoglobulin from 60 days before study intervention administration, or planned receipt throughout the study.
- Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza.
- Any participant who has received or plans to receive a modRNA-platform SARS CoV-2 vaccine within 14 days before or after study vaccination at Visit 1.
- Participation in other studies involving administration of a study intervention within 28 days prior to, and/or during, participation in this study.
- Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Quadrivalent influenza vaccine, ≥65 years of age Quadrivalent influenza vaccine Licensed quadrivalent influenza vaccine (single dose), participants ≥65 years of age Quadrivalent influenza modRNA vaccine, ≥65 years of age Quadrivalent influenza modRNA vaccine Quadrivalent influenza modRNA vaccine (single dose), participants ≥65 years of age Quadrivalent influenza modRNA vaccine, 18 through 64 years of age Quadrivalent influenza modRNA vaccine Quadrivalent influenza modRNA vaccine (single dose), participants 18 through 64 years of age Quadrivalent influenza vaccine, 18 through 64 years of age Quadrivalent influenza vaccine Licensed quadrivalent influenza vaccine (single dose), participants 18 through 64 years of age
- Primary Outcome Measures
Name Time Method Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years Day 15 to surveillance cut-off (approximately 6 months) LCI was defined as influenza infection confirmed through through reverse transcription- polymerase chain reaction (RT-PCR) or culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptoms concurrently with at least 1 systemic symptoms. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of Laboratory-Confirmed Influenza (LCI) Cases With Associated Per-Protocol Influenza-Like Illness (ILI) Caused by Any Strain at Least 14 Days After Vaccination: >= 65 Years Day 15 up to primary surveillance cut-off (approximately 1 year) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptoms concurrently with at least 1 systemic symptoms. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting Any Local Reactions Within 7 Days After Study Vaccination: 18-64 Years From Day 1 to Day 7 after study vaccination Local reactions included redness, swelling and pain at the injection site and were recorded by participants in an e-diary. All local reactions were graded based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure data is reported for any local reaction and any grade.
Percentage of Participants Reporting Any Local Reactions Within 7 Days After Study Vaccination: >=65 Years From Day 1 to Day 7 after study vaccination Local reactions included redness, swelling and pain at the injection site and were recorded by participants in an e-diary. All local reactions were graded based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure data is reported for any local reaction and any grade.
Percentage of Participants Reporting Any Systemic Events Within 7 Days After Study Vaccination: 18-64 Years From Day 1 to Day 7 after study vaccination Systemic events (vomiting, diarrhoea, headache, Fatigue/tiredness, chills, new or worsened muscle pain and joint pain) were recorded by participants in an e-diary. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure data is reported for any systemic reaction and any grade.
Percentage of Participants Reporting Any Systemic Events Within 7 Days After Study Vaccination: >=65 Years From Day 1 to Day 7 after study vaccination Systemic events (vomiting, diarrhoea, headache, Fatigue/tiredness, chills, new or worsened muscle pain and joint pain) were recorded by participants in an e-diary. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure data is reported for any systemic reaction and any grade.
Percentage of Participants Reporting Adverse Events (AEs) From Study Vaccination Through 4 Weeks After Study Vaccination: 18-64 Years From study vaccination on Day 1 through 4 weeks after study vaccination An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Results excluded local reactions and systemic events data.
Percentage of Participants Reporting AEs From Study Vaccination Through 4 Weeks After Study Vaccination: >=65 Years From study vaccination on Day 1 through 4 weeks after study vaccination An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Results excluded local reactions and systemic events data.
Percentage of Participants Reporting AEs From Study Vaccination Through 4 Weeks After Study Vaccination: >=18 Years From study vaccination on Day 1 through 4 weeks after study vaccination An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Results excluded local reactions and systemic events data.
Percentage of Participants Reporting Serious Adverse Events (SAEs) From Study Vaccination Through 6 Months After Study Vaccination: 18-64 Years From Day 1 up to 6 months after vaccination An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect.
Percentage of Participants Reporting SAEs From Study Vaccination Through 6 Months After Study Vaccination: >=65 Years From Day 1 up to 6 months after vaccination An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect.
Percentage of Participants Reporting SAEs From Study Vaccination Through 6 Months After Study Vaccination: >=18 Years From Day 1 up to 6 months after vaccination An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect.
- Secondary Outcome Measures
Name Time Method HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline HAI GMTs at Baseline for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years Baseline Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by All Matched Strains at Least 14 Days After Vaccination: 18-64 Years Day 15 to surveillance cut-off (approximately 6 months) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by All Matched Strains at Least 14 Days After Vaccination: >=65 Years Day 15 up to primary surveillance cut-off (approximately 1 year) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: 18-64 Years Before vaccination (Baseline) to 4 weeks after vaccination GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years Before vaccination (Baseline) to 4 weeks after vaccination GMFRs were defined as ratios of the results after vaccination to the results before vaccination.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline and 4 weeks after vaccination Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline and 4 weeks after vaccination HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: 18-64 Years Baseline and 4 weeks after vaccination HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline and 4 weeks after vaccination HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern- Based on HAI Assay 2: 18-64 Years Before vaccination (Baseline) to 4 weeks after vaccination HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years Before vaccination (Baseline) to 4 weeks after vaccination GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for the 2023 Southern Hemisphere - Based on HAI Assay 2: 18-64 Years 4 weeks after vaccination Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years 4 weeks after vaccination Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: 18-64 Years Baseline and 4 weeks after vaccination Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline and 4 weeks after vaccination HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline and 4 weeks after vaccination HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline and 4 weeks after vaccination HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 1: 18-64 Years Before Vaccination (baseline) to 4 weeks after vaccination HAI GMFR Before Vaccination to 4 Weeks After Vaccination for the 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Before vaccination (baseline) to 4 weeks after vaccination GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: 18-64 Years 4 weeks after vaccination Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 weeks after vaccination Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline and 4 weeks after vaccination Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline and 4 weeks after vaccination Percentage of Participants Reporting First Episode of Culture Confirmed Influenza (CCI) With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years Day 15 to surveillance cut-off (approximately 6 months) CCI was defined as influenza infection confirmed through culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of CCI With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: >=65 Years Day 15 up to primary surveillance cut-off (approximately 1 year) CCI was defined as influenza infection confirmed through culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by Modified Centers for Disease Control and Prevention (CDC) Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years Day 15 to surveillance cut-off (approximately 6 months) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by Modified CDC Caused by Any Strain at Least 14 Days After Vaccination: >=65 Years Day 15 up to primary surveillance cut-off (approximately 1 year) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. ILI defined modified CDC: occurrence (new onset or worsening of preexisting condition) of at least 1 of the following respiratory symptoms concurrently with an oral temperature \>37.2 deg C (\>99.0 deg F), sore throat or cough. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by World Health Organization (WHO) Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years Day 15 to surveillance cut-off (approximately 6 months) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. ILI as per WHO was defined as occurrence (new onset or worsening of preexisting condition) of a cough concurrently with an oral temperature \>=38.0 deg C (\>= 100.4 deg F). Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by WHO Caused by Any Strain at Least 14 Days After Vaccination: >=65 Years Day 15 up to primary surveillance cut-off (approximately 1 year) LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. ILI as per WHO was defined as occurrence (new onset or worsening of preexisting condition) of a cough concurrently with an oral temperature \>=38.0 deg C (\>= 100.4 deg F). Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode Cases of Influenza as Confirmed by RT-PCR or Local RT-PCR or Culture, With Associated Per-Protocol ILI at Least 14 Days After Vaccination: 18-64 Years Day 15 to surveillance cut-off (approximately 6 months) Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
Percentage of Participants Reporting First Episode Cases of Influenza as Confirmed by Central RT-PCR or Local RT-PCR or Culture, With Associated Per-Protocol ILI at Least 14 Days After Vaccination: >=65 Years Day 15 up to primary surveillance cut-off (approximately 1 year) Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV at 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years 4 Weeks after vaccination Geometric mean titers (GMTs) and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution) and were reported in the descriptive section. Geometric mean ratios (GMRs) were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline and 4 weeks after vaccination HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution) and were reported in the descriptive section. GMRs were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years 4 Weeks after vaccination Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest. Percentage of participants achieving seroconversion for each strain at 4 weeks after vaccination and exact 2-sided 95% CI is presented in the descriptive section. Difference in percentage of participants (qIRV - QIV) achieving HAI seroconversion for each strain at 4 weeks after vaccination is presented in the statistical analysis section.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest. Percentage of participants achieving seroconversion for each strain at 4 weeks after vaccination and exact 2-sided 95% CI is presented in the descriptive section. Difference in percentage of participants (qIRV - QIV) achieving HAI seroconversion for each strain at 4 weeks after vaccination is presented in the statistical analysis section.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 1: 18-64 Years 4 Weeks after vaccination GMTs and 2-sided 95% CIs were reported in the descriptive section. GMRs were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination GMTs and 2-sided 95% CIs were reported in the descriptive section. GMRs were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere-Based on HAI Assay 1: 18-64 Years 4 Weeks after vaccination Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest. Percentage of participants achieving seroconversion for each strain at 4 weeks after vaccination and exact 2-sided 95% CI is presented in the descriptive section. Difference in percentage of participants (qIRV - QIV) achieving HAI seroconversion for each strain at 4 weeks after vaccination is presented in the statistical analysis section.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest. Percentage of participants achieving seroconversion for each strain at 4 weeks after vaccination and exact 2-sided 95% CI is presented in the descriptive section. Difference in percentage of participants (qIRV - QIV) achieving HAI seroconversion for each strain at 4 weeks after vaccination is presented in the statistical analysis section.
HAI GMTs at Baseline for the 2022-2023 Northern Hemisphere - Based on HAI Assay 2: 18-64 Years Baseline (Before Vaccination) HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline (Before Vaccination) HAI Geometric Mean Fold Rise (GMFR) From Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years Before vaccination (Baseline) to 4 weeks after vaccination GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years Before vaccination (Baseline) to 4 weeks after vaccination GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years Baseline and 4 weeks after vaccination
Trial Locations
- Locations (299)
P3 Research - Wellington
🇳🇿Wellington, New Zealand
De La Salle Health Sciences Institute
🇵🇭Dasmarinas City, Philippines
De La Salle Medical and Health Sciences Institute
🇵🇭Dasmarinas, Philippines
St. Paul's Hospital of Iloilo, Inc.
🇵🇭Iloilo City, Philippines
Iloilo Doctors' Hospital
🇵🇭Iloilo, Philippines
Philippine General Hospital
🇵🇭Manila, Philippines
Synergy Biomed Research Institute
🇿🇦East London, Eastern CAPE, South Africa
Phoenix Pharma
🇿🇦Port Elizabeth, Eastern CAPE, South Africa
Iatros International
🇿🇦Bloemfontein, FREE State, South Africa
Josha Research
🇿🇦Bloemfontein, FREE State, South Africa
Worthwhile Clinical Trials
🇿🇦Benoni, Gauteng, South Africa
REIMED Reiger Park
🇿🇦Boksburg, Gauteng, South Africa
Soweto Clinical Trials Centre
🇿🇦Johannesburg, Gauteng, South Africa
Clinresco Centres
🇿🇦Kempton Park, Gauteng, South Africa
Ubuntu Clinical Research - Krugersdorp
🇿🇦Krugersdorp, Gauteng, South Africa
Ubuntu Clinical Research - Lenasia
🇿🇦Lenasia, Gauteng, South Africa
Zinakekele Medicall Centre
🇿🇦Moloto, Gauteng, South Africa
Jongaie Research
🇿🇦Pretoria West, Gauteng, South Africa
Emmed Research
🇿🇦Pretoria, Gauteng, South Africa
Global Clinical Trials
🇿🇦Pretoria, Gauteng, South Africa
Botho Ke Bontle Health Services
🇿🇦Pretoria, Gauteng, South Africa
Wits Clinical Research
🇿🇦Soweto, Gauteng, South Africa
Setshaba Research Centre
🇿🇦Tshwane, Gauteng, South Africa
Velocity Clinical Research, San Bernardino
🇺🇸Banning, California, United States
North Alabama Research Center
🇺🇸Athens, Alabama, United States
St. Vincent's Birmingham Hospital
🇺🇸Birmingham, Alabama, United States
Accel Research Sites Network - Birmingham Clinical Research Unit
🇺🇸Birmingham, Alabama, United States
Ross Bridge Medical Practice, LLC-CCT Research
🇺🇸Birmingham, Alabama, United States
SEC Clinical Research
🇺🇸Dothan, Alabama, United States
Lakeview Clinical Research
🇺🇸Guntersville, Alabama, United States
Medical Affiliated Research Center
🇺🇸Huntsville, Alabama, United States
Lenzmeier Family Medicine/CCT Research
🇺🇸Glendale, Arizona, United States
Aventiv Research
🇺🇸Mesa, Arizona, United States
Desert Clinical Research/ CCT Research
🇺🇸Mesa, Arizona, United States
HOPE Research Institute
🇺🇸Tempe, Arizona, United States
The Pain Center of Arizona
🇺🇸Phoenix, Arizona, United States
HOPE Research Institute - Phoenix
🇺🇸Phoenix, Arizona, United States
Foothills Research Center/ CCT Research
🇺🇸Phoenix, Arizona, United States
Epic Medical Research - Surprise
🇺🇸Surprise, Arizona, United States
Fiel Family and Sports Medicine, PC/CCT Research
🇺🇸Tempe, Arizona, United States
Noble Clinical Research
🇺🇸Tucson, Arizona, United States
Baptist Health Center For Clinical Research
🇺🇸Little Rock, Arkansas, United States
Applied Research Center of Arkansas
🇺🇸Little Rock, Arkansas, United States
Anaheim Clinical Trials
🇺🇸Anaheim, California, United States
Benchmark Research
🇺🇸Fort Worth, Texas, United States
Ascada Health PC dba Ascada Research
🇺🇸Fullerton, California, United States
Marvel Clinical Research
🇺🇸Huntington Beach, California, United States
Velocity Clinical Research, Huntington Park
🇺🇸Huntington Park, California, United States
Velocity Clinical Research, San Diego
🇺🇸La Mesa, California, United States
Orange County Research Center
🇺🇸Lake Forest, California, United States
Ark Clinical Research
🇺🇸Long Beach, California, United States
Kaiser Permanente
🇺🇸Los Angeles, California, United States
Velocity Clinical Research, Westlake
🇺🇸Los Angeles, California, United States
Velocity Clinical Research, North Hollywood
🇺🇸North Hollywood, California, United States
Center for Clinical Trials, LLC
🇺🇸Paramount, California, United States
Empire Clinical Research
🇺🇸Pomona, California, United States
Paradigm Clinical Research Centers, Inc
🇺🇸Wheat Ridge, Colorado, United States
Peninsula Research Associates
🇺🇸Rolling Hills Estates, California, United States
Artemis Institute for Clinical Research
🇺🇸San Diego, California, United States
Wr-McCr, Llc
🇺🇸San Diego, California, United States
California Research Foundation
🇺🇸San Diego, California, United States
Encompass Clinical Research
🇺🇸Spring Valley, California, United States
Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.
🇺🇸Toluca Lake, California, United States
Collaborative Neuroscience Research, LLC
🇺🇸Torrance, California, United States
Ark Clinical Research - Tustin
🇺🇸Tustin, California, United States
Diablo Clinical Research, Inc.
🇺🇸Walnut Creek, California, United States
Lynn Institute of Denver
🇺🇸Aurora, Colorado, United States
Tekton Research, LLC.
🇺🇸San Antonio, Texas, United States
New England Research Associates, LLC
🇺🇸Bridgeport, Connecticut, United States
Clinical Research Consulting
🇺🇸Milford, Connecticut, United States
New Haven Clinical Research Unit
🇺🇸New Haven, Connecticut, United States
Yale Cardiology
🇺🇸New Haven, Connecticut, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
Stamford Therapeutics Consortium
🇺🇸Stamford, Connecticut, United States
Washington Health Institute
🇺🇸Washington, District of Columbia, United States
JEM Research Institute
🇺🇸Lake Worth, Florida, United States
Tampa Bay Medical Research
🇺🇸Clearwater, Florida, United States
Alliance for Multispecialty Research, LLC
🇺🇸Norfolk, Virginia, United States
Universal Axon Clinical Research, LLC
🇺🇸Doral, Florida, United States
Fleming Island Center for Clinical Research
🇺🇸Fleming Island, Florida, United States
Proactive Clinical Research,LLC
🇺🇸Fort Lauderdale, Florida, United States
Robert B. Pritt, DO
🇺🇸Fort Myers, Florida, United States
Best Quality Research,Inc.
🇺🇸Hialeah, Florida, United States
Jacksonville Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
🇺🇸Jacksonville, Florida, United States
Health Awareness
🇺🇸Jupiter, Florida, United States
Wr-Msra.Llc
🇺🇸Lake City, Florida, United States
Accel Research Sites Network - Lakeland Clinical Research Unit
🇺🇸Lakeland, Florida, United States
Accel Research Sites - St. Petersburg Clinical Research Unit
🇺🇸Largo, Florida, United States
Accel Research Sites Network - Maitland Clinical Research Unit
🇺🇸Maitland, Florida, United States
Palm Springs Community Health Center
🇺🇸Miami Lakes, Florida, United States
Care Research - West Flagler Street
🇺🇸Miami, Florida, United States
Gerardo Polanco, MD
🇺🇸Miami, Florida, United States
Entrust Clinical Research
🇺🇸Miami, Florida, United States
Miami Dade Medical Research Institute, LLC
🇺🇸Miami, Florida, United States
Clinical Neuroscience Solutions, Inc.
🇺🇸Orlando, Florida, United States
Headlands Research Orlando
🇺🇸Orlando, Florida, United States
Innovation Medical Research Center
🇺🇸Palmetto Bay, Florida, United States
DBC Research USA
🇺🇸Pembroke Pines, Florida, United States
United Medical Research
🇺🇸Port Orange, Florida, United States
Genesis Clinical Research, LLC
🇺🇸Tampa, Florida, United States
Angels Clinical Research Institute
🇺🇸Tampa, Florida, United States
Clinical Site Partners, LLC dba Flourish Research
🇺🇸Winter Park, Florida, United States
Centricity Research Columbus Georgia Multispecialty
🇺🇸Columbus, Georgia, United States
IACT Health
🇺🇸Rincon, Georgia, United States
Centricity Research Rincon Pulmonology
🇺🇸Rincon, Georgia, United States
AGILE Clinical Research Trials, LLC
🇺🇸Sandy Springs, Georgia, United States
WR-Mount Vernon Clinical Research, LLC
🇺🇸Sandy Springs, Georgia, United States
CenExel iResearch, LLC
🇺🇸Savannah, Georgia, United States
Javara - Privia Medical Group Georgia - Savannah
🇺🇸Savannah, Georgia, United States
Velocity Clinical Research, Savannah
🇺🇸Savannah, Georgia, United States
Clinical Research Atlanta
🇺🇸Stockbridge, Georgia, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
🇺🇸Union City, Georgia, United States
East-West Medical Research Institute
🇺🇸Honolulu, Hawaii, United States
Clinical Research Prime
🇺🇸Idaho Falls, Idaho, United States
Solaris Clinical Research
🇺🇸Meridian, Idaho, United States
Koch Family Medicine
🇺🇸Morton, Illinois, United States
Accellacare - DuPage
🇺🇸Oak Lawn, Illinois, United States
MediSphere Medical Research Center - Evansville - West Franklin Street
🇺🇸Evansville, Indiana, United States
MediSphere Medical Research Center - EAST
🇺🇸Evansville, Indiana, United States
Velocity Clinical Research, Valparaiso
🇺🇸Valparaiso, Indiana, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
Velocity Clinical Research, Sioux City
🇺🇸Sioux City, Iowa, United States
Versailles Family Medicine / CCT Research
🇺🇸Versailles, Kentucky, United States
MedPharmics, LLC
🇺🇸Lafayette, Louisiana, United States
DelRicht Research
🇺🇸New Orleans, Louisiana, United States
Louisiana State University Health Sciences Shreveport
🇺🇸Shreveport, Louisiana, United States
Pharmaron
🇺🇸Baltimore, Maryland, United States
Advanced Primary and Geriatric Care - CCT Research
🇺🇸Rockville, Maryland, United States
Jadestone Clinical Research
🇺🇸Silver Spring, Maryland, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
ActivMed Practices and Research
🇺🇸Methuen, Massachusetts, United States
University of Massachusetts Chan Medical School
🇺🇸Worcester, Massachusetts, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Ascension St. John Hospital
🇺🇸Grosse Pointe Woods, Michigan, United States
Revival Research Institute, LLC
🇺🇸Sterling Heights, Michigan, United States
Oakland Medical Research
🇺🇸Troy, Michigan, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
🇺🇸Troy, Michigan, United States
Clinical Research Professionals
🇺🇸Chesterfield, Missouri, United States
Saint Louis University Center for Vaccine Development
🇺🇸Saint Louis, Missouri, United States
Sundance Clinical Research
🇺🇸Saint Louis, Missouri, United States
Bio-Kinetic Clinical Applications, LLD dba QPS-MO
🇺🇸Springfield, Missouri, United States
QPS Bio-Kinetic Clinical Applications (Patient Screening Only)
🇺🇸Springfield, Missouri, United States
Bozeman Health Deaconess Hospital
🇺🇸Bozeman, Montana, United States
Methodist Physicians Clinic/CCT Research
🇺🇸Fremont, Nebraska, United States
Velocity Clinical Research, Grand Island
🇺🇸Grand Island, Nebraska, United States
Be Well Clinical Studies
🇺🇸Lincoln, Nebraska, United States
Velocity Clinical Research, Norfolk
🇺🇸Norfolk, Nebraska, United States
Quality Clinical Research
🇺🇸Omaha, Nebraska, United States
Velocity Clinical Research, Omaha
🇺🇸Omaha, Nebraska, United States
Papillion Research Center/CCT Research
🇺🇸Papillion, Nebraska, United States
Excel Clinical Research, LLC
🇺🇸Las Vegas, Nevada, United States
Santa Rosa Medical Centers of Nevada / CCT Research
🇺🇸Las Vegas, Nevada, United States
ActivMed Practices & Research, LLC.
🇺🇸Portsmouth, New Hampshire, United States
David Jurist Research Building
🇺🇸Hackensack, New Jersey, United States
Hackensack University Medical Center Medical Plaza
🇺🇸Hackensack, New Jersey, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
South Jersey Infectious Disease
🇺🇸Somers Point, New Jersey, United States
Albuquerque Clinical Trials, Inc.
🇺🇸Albuquerque, New Mexico, United States
Velocity Clinical Research, Albuquerque
🇺🇸Albuquerque, New Mexico, United States
Smith Allergy & Asthma Specialists
🇺🇸Horseheads, New York, United States
NYU Langone Health
🇺🇸New York, New York, United States
Rochester Clinical Research, LLC
🇺🇸Rochester, New York, United States
Velocity Clinical Research, Vestal
🇺🇸Vestal, New York, United States
Accellacare - Cary
🇺🇸Cary, North Carolina, United States
Accellacare - Charlotte
🇺🇸Charlotte, North Carolina, United States
Carolina Institute for Clinical Research
🇺🇸Fayetteville, North Carolina, United States
PharmQuest Life Sciences, LLC
🇺🇸Greensboro, North Carolina, United States
Accellacare - Hickory
🇺🇸Hickory, North Carolina, United States
Monroe Biomedical Research
🇺🇸Monroe, North Carolina, United States
Accellacare - Raleigh
🇺🇸Raleigh, North Carolina, United States
M3 Wake Research, Inc.
🇺🇸Raleigh, North Carolina, United States
Accellacare - Rocky Mount
🇺🇸Rocky Mount, North Carolina, United States
Accellacare - Salisbury
🇺🇸Salisbury, North Carolina, United States
Accellacare - Wilmington
🇺🇸Wilmington, North Carolina, United States
Trial Management Associates - Wilmington - Floral Parkway
🇺🇸Wilmington, North Carolina, United States
Accellacare - Winston-Salem
🇺🇸Winston-Salem, North Carolina, United States
Plains Clinical Research Center
🇺🇸Fargo, North Dakota, United States
Plains Medical Clinic, LLC
🇺🇸Fargo, North Dakota, United States
CTI Clinical Research Center
🇺🇸Cincinnati, Ohio, United States
Meridian Clinical Research, LLC
🇺🇸Cincinnati, Ohio, United States
Cincinnati Children's Hospital Medical Center
🇺🇸Cincinnati, Ohio, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Senders Pediatrics
🇺🇸Cleveland, Ohio, United States
Velocity Clinical Research, Cleveland
🇺🇸Cleveland, Ohio, United States
Centricity Research Columbus Ohio Multispecialty
🇺🇸Columbus, Ohio, United States
Dayton Clinical Research
🇺🇸Dayton, Ohio, United States
WellNow Urgent Care & Research
🇺🇸Dayton, Ohio, United States
PriMED Clinical Research
🇺🇸Dayton, Ohio, United States
Lynn Institute of Norman
🇺🇸Norman, Oklahoma, United States
Lynn Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Velocity Clinical Research, Medford
🇺🇸Medford, Oregon, United States
Kaiser Permanente Northwest Center for Health Research
🇺🇸Portland, Oregon, United States
Lehigh Valley Health Network
🇺🇸Allentown, Pennsylvania, United States
Capital Area Research, LLC
🇺🇸Camp Hill, Pennsylvania, United States
Central Erie Primary Care
🇺🇸Erie, Pennsylvania, United States
Velocity Clinical Research, Providence
🇺🇸East Greenwich, Rhode Island, United States
Velocity Clinical Research, Anderson
🇺🇸Anderson, South Carolina, United States
Pharmacorp Clinical Trials
🇺🇸Charleston, South Carolina, United States
Velocity Clinical Research, Columbia
🇺🇸Columbia, South Carolina, United States
Velocity Clinical Research, Gaffney
🇺🇸Gaffney, South Carolina, United States
Tribe Clinical Research, LLC
🇺🇸Greenville, South Carolina, United States
Main Street Physician's Care
🇺🇸Little River, South Carolina, United States
Clinical Trials of South Carolina
🇺🇸Moncks Corner, South Carolina, United States
Trial Management Associates
🇺🇸Myrtle Beach, South Carolina, United States
Coastal Carolina Research Center
🇺🇸North Charleston, South Carolina, United States
Velocity Clinical Research, Spartanburg
🇺🇸Spartanburg, South Carolina, United States
Velocity Clinical Research, Union
🇺🇸Union, South Carolina, United States
Internal Medicine and Pediatric Associates of Bristol
🇺🇸Bristol, Tennessee, United States
WR-Clinsearch, LLC
🇺🇸Chattanooga, Tennessee, United States
Holston Medical Group
🇺🇸Kingsport, Tennessee, United States
New Phase Research and Development
🇺🇸Knoxville, Tennessee, United States
Accellacare US Inc., d/b/a Accellacare of Knoxville
🇺🇸Knoxville, Tennessee, United States
Clinical Neuroscience Solutions Inc.
🇺🇸Memphis, Tennessee, United States
Elligo Clinical Research Center
🇺🇸Austin, Texas, United States
Orion Clinical Research
🇺🇸Austin, Texas, United States
Velocity Clinical Research, Austin
🇺🇸Austin, Texas, United States
Headlands Research - Brownsville
🇺🇸Brownsville, Texas, United States
WR-Global Medical Research, LLC
🇺🇸Dallas, Texas, United States
DFW Clinical Research
🇺🇸Dallas, Texas, United States
North Texas Infectious Diseases Consultants, P.A
🇺🇸Dallas, Texas, United States
Epic Medical Research - DeSoto
🇺🇸DeSoto, Texas, United States
Proactive Clinical Research, LLC
🇺🇸Edinburg, Texas, United States
Texas Health Family Care
🇺🇸Fort Worth, Texas, United States
Allure Health
🇺🇸Friendswood, Texas, United States
Trio Clinical Trials
🇺🇸Houston, Texas, United States
Juno Research
🇺🇸Houston, Texas, United States
Prolato Clinical Research Center
🇺🇸Houston, Texas, United States
DM Clinical Research - Bellaire
🇺🇸Houston, Texas, United States
Santa Clara Family Clinic
🇺🇸Houston, Texas, United States
Dynamed Clinical Research, LP d/b/a DM Clinical Research
🇺🇸Humble, Texas, United States
Andres Garcia Zuniga, M.D., P.A.
🇺🇸Laredo, Texas, United States
SMS Clinical Research
🇺🇸Mesquite, Texas, United States
AIM Trials, LLC
🇺🇸Plano, Texas, United States
Clinical Trials of Texas, LLC
🇺🇸San Antonio, Texas, United States
IMA Clinical Research San Antonio
🇺🇸San Antonio, Texas, United States
Javara - Privia Medical Group North Texas - Stephenville
🇺🇸Stephenville, Texas, United States
Sugar Lakes Family Practice, PA
🇺🇸Sugar Land, Texas, United States
DM Clinical Research, Martin Diagnostic Clinic
🇺🇸Tomball, Texas, United States
Northwest Houston Heart Center
🇺🇸Tomball, Texas, United States
Crossroads Clinical Research
🇺🇸Victoria, Texas, United States
Cope Family Medicine / CCT Research
🇺🇸Bountiful, Utah, United States
South Ogden Family Medicine/ CCT Research
🇺🇸Ogden, Utah, United States
J. Lewis Research, Inc. / Foothill Family Clinic
🇺🇸Salt Lake City, Utah, United States
Olympus Family Medicine/CCT Research
🇺🇸Salt Lake City, Utah, United States
J. Lewis Research, Inc. / Foothill Family Clinic South
🇺🇸Salt Lake City, Utah, United States
J. Lewis Research, Inc. / Jordan River Family Medicine
🇺🇸South Jordan, Utah, United States
Springville Dermatology - Springville/CCT Research
🇺🇸Springville, Utah, United States
Velocity Clinical Research, Salt Lake City
🇺🇸West Jordan, Utah, United States
Clinical Alliance for Research and Education - Infectious Diseases (CARE-ID), LLC
🇺🇸Annandale, Virginia, United States
Charlottesville Medical Research
🇺🇸Charlottesville, Virginia, United States
Virginia Research Center
🇺🇸Midlothian, Virginia, United States
Health Research of Hampton Roads, Inc.
🇺🇸Newport News, Virginia, United States
Meridian Clinical Research LLC
🇺🇸Portsmouth, Virginia, United States
Clinical Research Partners, LLC
🇺🇸Richmond, Virginia, United States
Centricity Research Suffolk Primary Care
🇺🇸Suffolk, Virginia, United States
EvergreenHealth Medical Center
🇺🇸Kirkland, Washington, United States
EvergreenHealth
🇺🇸Kirkland, Washington, United States
Rainier Clinical Research Center
🇺🇸Renton, Washington, United States
Kaiser Permanente Washington Health Research Institute (KPWHRI)
🇺🇸Seattle, Washington, United States
Kaiser Permanente Washington Health Research Institute
🇺🇸Seattle, Washington, United States
Seattle Clinical Research Center
🇺🇸Seattle, Washington, United States
Allegiance Research Specialists, LLC
🇺🇸Wauwatosa, Wisconsin, United States
Fundacion Estudios Clinicos
🇦🇷Rosario, Santa FE, Argentina
Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L
🇦🇷San Miguel de Tucuman, Tucumán, Argentina
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
🇦🇷Buenos Aires, Argentina
Enroll SpA
🇨🇱Santiago, Región Metropolitana DE Santiago, Chile
Centro Skin Med Limitada
🇨🇱Santiago, Región Metropolitana DE Santiago, Chile
CECIM
🇨🇱Santiago, Región Metropolitana DE Santiago, Chile
Pacific Clinical Research Network - Rotorua
🇳🇿Rotorua, BAY OF Plenty, New Zealand
P3 Research - Tauranga
🇳🇿Tauranga, BAY OF Plenty, New Zealand
Pacific Clinical Research Network - Forte
🇳🇿Christchurch, Canterbury, New Zealand
P3 Research - Hawke's Bay
🇳🇿Hastings, Hawke's BAY, New Zealand
Lakeland Clinical Trials Waikato
🇳🇿Hamilton, Waikato, New Zealand
Lakeland Clinical Trials Wellington
🇳🇿Upper Hutt, Wellington, New Zealand
Southern Clinical Trials Totara
🇳🇿Auckland, New Zealand
Optimal Clinical Trials North
🇳🇿Auckland, New Zealand
Optimal Clinical Trials
🇳🇿Auckland, New Zealand
Southern Clinical Trials Tasman
🇳🇿Nelson, New Zealand
West Visayas State University Medical Center
🇵🇭Iloilo City, Iloilo, Philippines
Health Cube Medical Clinics
🇵🇭Mandaluyong, Metro Manila, Philippines
Tropical Disease Foundation
🇵🇭Makati, National Capital Region, Philippines
Mary Johnston Hospital
🇵🇭Manila, National Capital Region, Philippines
Lung Center of the Philippines
🇵🇭Quezon City, National Capital Region, Philippines
Far Eastern University Nicanor Reyes Medical Foundation
🇵🇭Quezon City, National Capital Region, Philippines
Adventist Hospital Palawan
🇵🇭Puerto Princesa, Palawan, Philippines
Synexus Watermeyer Clinical Research Centre
🇿🇦Val De Grace, Gauteng, South Africa
FCRN Clinical Trial Centre
🇿🇦Vereeniging, Gauteng, South Africa
Precise Clinical Solutions
🇿🇦Chatsworth, Kwazulu-natal, South Africa
Private Practice - Dr. Peter Sebastian
🇿🇦Chatsworth, Kwazulu-natal, South Africa
Synapta Clinical Research Centre
🇿🇦Durban, Kwazulu-natal, South Africa
MERCLINCO Middleburg
🇿🇦Middelburg, Mpumalanga, South Africa
Aurum Institute - Rustenburg
🇿🇦Rustenburg, North-west, South Africa
TREAD Research (Pty)Ltd
🇿🇦Cape Town, Western CAPE, South Africa
TASK Applied Science
🇿🇦Cape Town, Western CAPE, South Africa
Tiervlei Trial Centre
🇿🇦Cape Town, Western CAPE, South Africa
TREAD Research
🇿🇦Cape Town, Western CAPE, South Africa
Umzimkhulu Research Centre
🇿🇦uMzimkhulu, South Africa